Oncology Xagena
On 20 September 2010, orphan designation was granted by the European Commission for Vorinostat for the treatment of malignant mesothelioma.Malignant mesothelioma is a cancer that is usually caused by ...
In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene ( ALK ) have been associated with marked clinical responses to Crizotinib ( Xalkori ), an oral tyrosine kinas ...
The majority of patients with non-small cell lung cancer ( NSCLC ) present at the time of diagnosis with advanced disease. Subsets of patients are eligible for therapies targeted at mutated oncogene d ...
Afatinib ( Giotrif ) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LUX-Lung 3 ( LL3 ) has compared Afatinib with Cisplatin / Pemetrexed in 345 patients recrui ...
An established multivariate serum protein test can be used to classify patients according to whether they are likely to have a good or poor outcome after treatment with EGFR tyrosine-kinase inhibitors ...
The efficacy of the ALK inhibitor, Crizotinib ( Xalkori ) as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer ( NSCLC ) is unknown. A ...
Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung 3 and LUX-Lung 6, in patients with EGFR-mutant advanced non ...
Cancer Drugs Fund ( CDF ) Panel has assessed the application for single agent Pemetrexed ( Alimta ) to remain in the CDF as 2nd line treatment for patients with non-squamous ( NS ) non-small cell lun ...
Cancer Drugs Fund ( CDF ) Panel has assessed the application was for single agent Pemetrexed ( Alimta ) to remain in the CDF as maintenance treatment for patients with locally advanced or metastatic ...
A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...
The European Commission ( EC ) has approved Varuby ( oral Rolapitant tablets ) for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in ...
Updated results from Cohort G of the phase 2 KEYNOTE-021 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Pemetrexed and Carboplatin ( Pem/Carbo ) in patients ...
The U.S. Food and Drug Administration ( FDA ) has approved an expanded label for Keytruda, an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line ...
In KEYNOTE-189, Pembrolizumab ( Keytruda ) plus Pemetrexed ( Alimta ) and Platinum provided superior overall survival ( OS ) ( hazard ratio, HR 0.49, P less than 0.00001 ) and progression-free surviva ...
The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall survival ( OS ), progression-free survival ( P ...
